You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
CB 5083 New
Biological Activity for CB 5083
CB 5083 is a potent p97 inhibitor, inhibiting the D2 ATPase domain (IC50 = 11 nM). CB 5083 shows broad antitumor activity and inhibits tumor growth in vivo. CB 5083 is cytotoxic to A549 cancer cells (IC50 = 680 nM), increases CHOP and GRP78 protein levels and results in the loss of aggresomes.
Technical Data for CB 5083
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CB 5083
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CB 5083
The following data is based on the product molecular weight 413.48. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.42 mL||12.09 mL||24.18 mL|
|5 mM||0.48 mL||2.42 mL||4.84 mL|
|10 mM||0.24 mL||1.21 mL||2.42 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References for CB 5083
References are publications that support the biological activity of the product.
Mukkavalli et al (2021) The p97-UBXN1 complex regulates aggresome formation. J.Cell Sci. 134 PMID: 33712450
Vekaria et al (2016) Targeting p97 to disrupt protein homeostasis in cancer. Front.Oncol. 6 PMID: 27536557
Vekaria et al (2019) Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. Leukemia 33 1675 PMID: 30664664
Huryn et al (2019) p97: an emerging target for cancer, neurodegenerative diseases, and viral infections. J.Med.Chem. 63 1892 PMID: 31550150
Le Moigne et al (2017) The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma. Mol.Cancer Ther. 16 2375 PMID: 28878026
If you know of a relevant reference for CB 5083, please let us know.
View Related Products by Product Action
Keywords: CB 5083, CB 5083 supplier, CB5083, p97, atpases, inhibitors, potent, tumor, antitumor, aggresome, ATPase, 7379, Tocris Bioscience
Citations for CB 5083
Citations are publications that use Tocris products.
Currently there are no citations for CB 5083. Do you know of a great paper that uses CB 5083 from Tocris? Please let us know.
Reviews for CB 5083
There are currently no reviews for this product. Be the first to review CB 5083 and earn rewards!
Have you used CB 5083?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.